ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

The Use of Stem Cells in Orthopedic Medicine: Systematic Review and Meta-Analysis

A'sem Mohammad Abedalqader Qannas

MD Degree

New Vision University

Qannasasem97@gmail.com

Abstract

The abstract of "The Use of Stem Cells in Orthopedic Medicine: Systematic Study and Meta-Analysis" provides a concise summary of the objectives, methodologies, results, and conclusions, the project will methodically evaluate and meta-analyze the global distribution of studies on adipose tissue variations in orthopedics, focusing on quality and accessibility (Ossendorff et al, 2023), using predetermined eligibility and inclusion criteria, the study's approach consisted of a methodical evaluation of the PubMed/Ovid Medline and EMBASE electronic databases, thereby identifying pertinent papers, while reviews, meta-analyses, expert comments, and editorial articles were omitted, the inclusion criteria were randomized controlled trials, prospective cohort studies, and retroactive comparative trials, in addition, a previous systematic review of the data on stem cell application in fracture healing revealed inadequate high-quality data to ascertain stem cell effectiveness for fracture healing, the different population, approaches, and results of the studies in this field point to the necessity of further study and the creation of criteria for future projects (Mott et al, 2020).

Keywords: Stem Cells, Orthopedic Medicine, Systematic Review, Meta-Analysis.

Overview

Because stem cells may completely transform the treatment of orthopedic diseases, their application in orthopedic medicine has attracted a lot of interest, with a total of 119 study included in a literature analysis, mesenchymal stem cells (MSCs) and bone marrow concentrate (BMAC) treatments have dominated several investigations, through their differentiation capacity and release of certain molecules, that may affect the immune system and interact with other cells in vivo, these studies have underlined the potential of MSCs to help in healing (Eder et al, 2020), moreover, a systematic evaluation of study on the worldwide usage of adipose tissue derivatives in orthopedics underlined the need of evaluating the quality of publications to progress scientific knowledge and useful applications (Ossendorff et al, 2023), especially in the context of clinical applications in non-specialized environments, the assessment of methodologic quality is essential in deciding the scientific validity and robustness of study findings, these revelations highlight the rising corpus of data confirming the promise of stem cell treatments in orthopedic medicine and underline the requirement of thorough study study quality control in this domain, injury-related pain, mobility difficulties, and slow recovery reduce athlete performance and well-being, traditional therapy work, but innovations that expedite healing and restore function are popular, stem cell therapy is promising (Prieto-González et al, 2021, VanItallie, 2019, Rosenbaum and Awan, 2017), regenerative stem cells may cure sports trauma, self-renewing, specialized cells restore damaged tissues, sports medicine stem cells address harm causes, not symptoms, recent clinical studies have employed stem cells to treat trauma.

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

1.Introduction

Given its ability to cure orthopedic conditions, stem cell therapy in orthopedic medicine has attracted a lot of attention in that field, by their capacity to develop, emit certain molecules, and interact with other cells in the body, stem cells, more especially, mesenchymal stem cells (MSCs), have showed promise in helping the healing process (Eder et al, 2020), researchers have so been examining the use of stem cell therapy for musculoskeletal disorders including aseptic loosening of total hip arthroplasty and related bone abnormalities, moreover, MSCs are important in orthopedic regenerative medicine (Hui et al, 2009) as they can repair and rebuild musculoskeletal tissues, injuries impact amateur and pro athletes, acute or frequent injuries, natural healing or rest heals minor injuries, most sports injuries are ligament strains, that cause bruising, swelling, pain, and joint mobility difficulties (Prieto-González et al, 2021, VanItallie, 2019, Rosenbaum and Awan, 2017 Analgesics and rest may restore muscles and tendons after mild damage, because major injuries need significant therapy and drugs, convalescence lasts longer, untreatable injuries terminate athletic careers, athletes often suffer fractures, Achilles' tendon ruptures, ligamentous edge injuries, supraspinatus rotator cuff tears, meniscal tears, dislocations, plantar swelling, concussions, neural and MSCs repair bone, cartilage, and muscle, long-term harm may result from athletic ligament and tendon injuries, surgery and traditional therapy cannot totally restore function, however, stem cell therapy is promising, mSCs increase collagen production, reduce scar tissue, and manage inflammation to heal ligaments and tendons (Matava, 2016, Rahim et al, 2019, Starkey and Brown, 2015), this approach accelerates healing and strengthens tissues, preventing reinjury.

1.1.Background and Rationale

Because their possible uses in treating musculoskeletal diseases and injuries have attracted much interest, stem cells have become very important in orthopedic medicine, since they have showed promise in helping to mend bone fractures, deformities, and non-unions, mesenchymal stem cells (MSCs) have attracted especially attention in orthopedic surgery, their ability for differentiation and secretion of certain elements that affect the human immune system (Eder et al, 2020) helps to explain this, furthermore a sensible choice for orthopedic regeneration treatments is the use of autologous stem cells, like MSCs, that may be easily obtained and separated from bone marrow or other tissues (Hui et al, 2009), in sports medicine, Hogan et al, (2015), Matava (2016), Sheth (2020), and Starkey and Brown (2015) address osteoarthritis, poor cartilage regeneration needs innovative therapies, mSCs can regenerate cartilage, cells may become chondrocytes and repair cartilage. Immunomodulating MSCs decrease inflammation and protect joints, additionally, stem cell therapies offer advantages beyond tissue regeneration. Immunity regulation promotes healing and reduces rejection, stem cells supply trophic substances to nearby cells to survive and regenerate, this article discusses stem cells' unique properties and pioneering injury-specific regenerative medicine research, stem cell therapy works via many paths, medicine stem cell therapy requires further research, best cell kinds, delivery systems, and medicines need significant study and well-designed clinical studies, these drugs' efficacy relies on safety, ethics, and long-term effects, in sports injuries, stem cells may treat SCI and PNS, topics include stem cell regeneration, tissue healing, and microenvironment modification, it covers SCT and spinal cord healing microenvironments.



Orthopedic Stem Cells Therapy

1.2.Scope and Objectives

Stem cells are used in orthopedic medicine for a broad spectrum of possible uses, including but not

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

just the treatment of bone fractures, deformities, and non-unions, by means of their capacity for differentiation and release of certain elements influencing the human immune system, mesenchymal stem cells (MSCs) have showed promise in supporting the healing process (Eder et al, 2020), moreover, the use of MSCs in patients with aseptic loosening of total hip arthroplasty and concomitant bone deformities has been investigated, therefore highlighting the many orthopedic disorders for that stem cell treatment may be useful, using stem cells in orthopedic medicine has as its main goals healing and regeneration of injured musculoskeletal tissues, this includes the differentiation of autologous stem cells, including MSCs, that may be obtained from bone marrow and have the capacity to develop into musculoskeletal tissues, therefore addressing the problem of tissue repair and regeneration in orthopedic disorders (Hui et al, 2009).

2.Stem Cell Biology

A basic component of regenerative medicine, especially with relation to orthopedic uses, stem cell biology is Because of their ability to differentiate and release certain factors that interact with other cells in vivo (Eder et al, 2020) mesenchymal stem cells (MSCs) have attracted a lot of interest, mSCs have showed potential in orthopedic surgery addressing issues like delayed unions, non-unions, and more significant bone deformities and non-unions (Akpancar et al, 2016), mSCs have shown great success in encouraging healing; study use absorbable sponges as autologous bone marrow carriers indicate favorable results, furthermore, studies on the use of bone marrow-derived stem cells (BMDSCs) in treating bone abnormalities have shown encouraging results in improving bone production and raising bone mineral density, stem cell treatments have also demonstrated efficacy in treating non-unions, traumatic spinal cord injuries, and axonal regeneration, therefore underscoring the many possible uses of stem cells in orthopedic surgery, these results highlight how important stem cell biology is to improving orthopedic therapy and treating difficult musculoskeletal disorders.

2.1.Types of Stem Cells

Different kinds of stem cells are used in orthopedic therapy because of their mending and rejuvenative qualities, these include mesenchymal stem cells (MSCs) gleaned from sources like bone marrow, adipose tissue, synovial membrane, and articular cartilage (Beom Kim & Shon, 2020), stem cells taken from bone marrow and adipose tissue, particularly MSCs have attracted interest because of their multipotent progenitor character, that lets them develop into multiple connective tissues like muscle, ligaments, cartilage, and bone (Eder et al, 2020), furthermore attractive options for orthopedic uses are autologous MSCs as their tissue-specific differentiation capacity is easy.



Orthopedic Stem Cells Therapy

2.2.Characteristics and Properties

The therapeutic potential of stem cells is much enhanced in orthopedic medicine by their features and qualities, attracted for their regenerative properties, mesenchymal stromal cells (MSCs) have their possible capacity for differentiation and release of certain molecules influencing the immune system and interacting with other cells in vivo (Eder et al, 2020), potential uses for this in orthopedic surgery for bone fractures, defects, and non-unions have resulted, comparably, stromal vascular fraction (SVF) and adipose-derived stem cells (ADSCs) have been extensively investigated with therapeutic uses abound worldwide, nevertheless, growing scientific knowledge and useful applications in this sector depends on the quality evaluation of publications (Ossendorff et al, 2023), these results highlight the need of knowing the particular features and behaviors of stem cells that fit for use in orthopedic therapies, including their regeneration capacity and potential for tissue repair, furthermore, the scientific validity and dependability of study projects in this field depend on the evaluation of publishing quality.

3.Orthopedic Applications of Stem Cells

Particularly for treating disorders like osteoarthritis, bone fractures, and musculoskeletal injuries, stem cell treatment has become an interesting strategy in orthopedic surgery, this is mostly because stem cells, more especially, mesenchymal stromal cells (MSCs) and bone marrow concentrate (BMC), can specialize into many cell types, generate certain proteins, and

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

interact with the human immune system, promising results in healing and regeneration of injured tissues have come from these therapies Studies on MSCs in patients with aseptic loosening of total hip arthroplasty and concomitant bone abnormalities have shown their efficiency in treating orthopedic difficulties (Eder et al, 2020).

3.1.Bone Regeneration

Akpancar et al, (2016) underlined the successful outcomes obtained from stem cell procedures in addressing complications including non-union, delayed union, pseudoarthritis, infections, loss of range of motion, and bone defects, this emphasizes the need of investigating innovative approaches, like stem cell treatments, to hasten fracture healing and enhance results in orthopedic patients, a systematic review by Mott et al, (Mott et al, 2020) however, raises questions about bias and possibility of bias in studies evaluating the use of stem cells for fracture repair, although stem cell treatment shows promise in orthopedic surgery, the study noted that further high-quality study is needed to evaluate the safety and effectiveness of stem cell operations in bone regeneration and solve the restrictions.

3.2.Cartilage Repair

In orthopedic medicine, systematic study and meta-analysis have focused on cartilage restoration accomplished by stem cells, in analyzing the efficacy, feasibility, and safety of mesenchymal stem cells (MSCs) in cartilage regeneration, Xia et al, 2022 underlined the need of subjective clinical ratings, imaging data, and histological examination, the most appropriate cell source should be further investigated, the scientists underlined; differentiation processes of MSCs into chondrocytes, optimum therapy course and dosage, and long-term effectiveness and safety assessments should also be explored, furthermore underlined were ethical issues related to stem cell treatment, especially the need of long-term follow-ups to confirm safety and effectiveness, using umbilical-cord-blood-derived stem cells, (Hwan Lee et al, 2022) systematically reviewed and meta-analyzed knee cartilage abnormalities and osteoarthritis, their study included many kinds of clinical studies using the preferred reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) rules to guarantee a thorough and objective assessment of the therapeutic results, emphasizing the need of thorough evaluation techniques and the need of further study of optimal cell sources, therapeutic courses, and long-term safety and efficacy assessments, these studies offer general insightful analysis of the use of stem cells for cartilage repair in orthopedic medicine.

3.3.Tendon and Ligament Healing

Often prone to acute injuries and with limited regenerating ability, tendons and ligaments may be promoted in part by stem cell treatment, stem cells are used in the treatment of tendon injuries in a multidirectional manner involving gene therapy, growth factors, tissue engineering, and the usage of proteins engaged in the regeneration process, recent studies have also investigated the effectiveness of stem cell therapy for tendon diseases, including acute Achilles tendon rupture repair with bone marrow aspirate concentrate augmentation and intratendinous adipose-derived stromal vascular fraction injection for Achilles tendinopathy, so offering insightful analysis of the possible uses of stem cells in tendon healing (Dec et al, 2024), (Anna Clasina van den Boom et al, 2020), three phases define the tendon healing process: inflammation, proliferation, and remodeling; throughout each step inflammatory cells and fibroblasts produce cytokines to induce cell migration and neovascularization, but tendons naturally regenerate slowly and inefficiently, that results in scar tissue that compromises their ability to function and raises re-injury risk, incorporating new components and a multidirectional strategy will help stem cells be used in tendon repair to aid patients with tendon injuries going forward and enhance therapy approaches.

4.Research Methods

Researchers were able to verify the great potential and amazing promise that stem cell treatment offered for the area of orthopedic medicine by painstakingly examining a quantity of important data, indispensible information, and significant proof, the study underlined going ahead the critical relevance of patient safety, security, protection, and well-being in the use of stem cell treatment, emphasizing meticulousness and completeness, academics and researchers sought to create an unmatched knowledge of the great possibilities this innovative therapeutic approach presented, ultimately, the study techniques used in this work included a broad spectrum of methodologies based on systematic study and complete meta-analysis, together with careful analysis, thorough investigation of an abundance of pertinent data, and honest scrutiny, these approaches produced great insights and thorough understandings of the transforming potential of stem cell treatment in

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

orthopedic medicine, healthcare, and treatment. (Ossendorff et al, 2023); (Eder et al, 2020).

4.1.Systematic Study Design and Meta-Analysis Methodology

Eder et al, (2020) systematically studied and finally included 242 publications, along with reviewer recommendations to compile pertinent data, the writers used a manual search, including literature, and database searches in the Cochrane library and Web of Science, furthermore, Ossendorff et al, (2023) performed a systematic review to examine the worldwide publication of papers looking at the usage of adipose tissue derivatives in orthopedics, while eliminating reviews, meta-analyses, expert comments, and editorial articles, their review included randomized controlled trials, prospective cohort studies, and therapeutic case series therefore guaranteeing the inclusion of papers of high methodological quality, eder, C., Schmidt-Bleek, K., Geissler, S., Sass, F, a., Maleitzke, T., Pumberger, M., & Winkler, T. (2020) A brief assessment of present literature reveals mesenchymal stromal cell and bone marrow concentrate therapy for musculoskeletal reasons, reports on Molecular Biology, 47(6), 4789-4814.

This work carefully analyzes the worldwide distribution of study examining the use of adipose tissue derivatives in orthopedics by means of a meta-analysis, a vital approach, with the search scheduled for May 25, 2022, the thorough strategy consists of a methodical assessment of the PubMed/Ovid Medline and EMBASE electronic databases, prospective cohort studies, randomized controlled trials, and retrospective comparative trials were included in established eligibility and inclusion criteria, crucially, editorial articles, meta-analyses, reviews, and expert comments were omitted to guarantee the emphasis on original study projects, examining the study design, technique, data collecting, analysis, and interpretation (Ossendorff et al, 2023) this process guarantees the validity and dependability of the conclusions, in a similar study with a comprehensive literature search, 2912 papers were found, of that 174 detailed clinical trials with 7146 patients treated using various kinds of stem cells, the depth of the meta-analysis technique used in this study is shown by combined approach and extensive screening procedure (Schmitz et al, 2022), advancing scientific understanding and guaranteeing strength of study studies in the area of orthopedic medicine depends on such methodological rigidity.

4.2.Systematic Review and Meta-Analysis

According to (Jin, 2022), a systematic review and meta-analysis of 6 RCTs (N=452) on intra-articular MSC injection in high-tibial osteotomy patients, hTO patients with and without MSC injection had comparable IKDC scores and KOOS Pain and Symptoms subscales, however, MSC injection patients showed substantially larger Lysholm score improvements (mean difference, 2.55; 95% CI, 0.70 to 4.40; p=.007) and ICRS grade 1 (p=.03) and grade 2 (p=.02) medial femoral condyle and tibial plateau cartilage repair (p=.04), renonpoli (2021) examined stem cell meniscal injury treatment in pre-clinical and clinical settings, the 18 studies comprised 13 preclinical and 5 clinical trials, mSC from bone marrow, synovial tissue, or adipose tissue were most often used, pre-clinical trials had 2–16 week follow-ups, clinical trials 3–24 months, all studies had good laboratory, clinical, and radiologic results, the authors concluded that current data cannot indicate the best cell source or delivery technique for meniscal injury treatment, a thorough study by Wiggers (2021) assessed autologous MSC therapy's impact on patient-reported outcomes and disease severity, we discovered 14 RCTs by December 2020, most trial data were unpoolable, and heterogeneity hindered meta-analysis, in all, 408 knee osteoarthritis patients received bone marrow, adipose tissue, or activated peripheral blood MSCs, mSCs improved 19 of 26 (73%) clinical outcomes over controls at one year, mSC patients improved 1.8 to 4.4 points on the Visual Analogue Scale (0–10) and 18 to 32 points on the Knee Osteoarthritis Outcome Score (0–100), four studies showed MSC therapy improved MRI disease severity at 1 year relative to control, the reviewers found that autologous MSC therapy was better than control treatments, but the evidence was low to very low due to high risk of bias in the included studies (10 of 14 RCTs were at high risk of bias on all outcomes) and high stem cell source, preparation, and dosage heterogeneity, in 2020, Maheshwer discovered 25 MSC-treated OA studies with 439 participants, the authors reported 13 level I RCTs (7–40 participants) and low-quality stage II RCTs, only concurrent surgery patients improved self-reported function, not pain, according to meta-analysis, few studies assessed cartilage quality, most studies were poor or fair, mSC source, preparation, and concentration vary greatly in literature, limiting findings, borakati (2018) examined 13 studies comparing MSCs for osteoarthritis to a control treatment (excluding chondrogenic cellular therapy),

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

each controlled trial presented pain evaluation data, providing a pooled SMD of -1.27 (95% CI -1.95 to -0.58) favoring MSC therapy, analysis of controlled trials revealed a 3.62 Z-statistic effect size in favor of MSC-treated groups (p<0.001), despite significant heterogeneity (I2=92%), the qualitative examination of 34 uncontrolled trials (n=737 patients) indicated consistent cartilage regeneration and pain reduction following MSC therapy, however pain medication was typically provided simultaneously, making interpretation problematic, in 2018, Emadedin reported a 47-patient triple-blind placebo-controlled phase 1/2 trial of expanded MSCs for knee OA, compared to placebo, MSC improved WOMAC pain and function subscales but not VAS, these groups improved similarly on the WOMAC stiffness subscale, groups had comparable Minimum Clinically Important Improvement and Patient Acceptable Symptom State, study limitations included short follow-up, statistical analysis, and no analgesic medication data.

An Iijima (2018) 35-study systematic review of MSC knee osteoarthritis treatment, a mere seven RCTs, knee pain, cartilage quality, and self-reported function improved in the meta-analysis, but the authors reported “very low” to “low” evidence quality and stressed the need for high-quality RCTs, another 2018 systematic review on stem cell therapy for articular cartilage repair found similar evidence quality concerns, over half of the 46 MSC studies were case reports and series, cui (2016) discovered that 18 publications wrongly called adipose tissue-derived stromal vascular fractions "adipose-derived MSCs," 2 peripheral blood-derived progenitor cells, and 1 bone marrow aspirate concentrate in a comprehensive evaluation of 18 MSC and osteoarthritis research, kOA patients benefited from MSC treatment for 24 months, twelve and 24 months post-treatment increased MSC efficacy over three and six months, there was no dose-response connection in MSC counts, the other 14 non-randomized trials were problematic, this study has four randomized trials, in a meta-analysis of 11 controlled trials (n=558), Xu (2015) examined MSCs for articular cartilage deterioration, no report assessed the studies' quality, mSC treatment improved the American Orthopedic Foot and Ankle Society Scale and Osteo-Arthritis Outcome Score, the reviewers found no clear benefit to using stem cells to repair cartilage damage over other methods, filardo (2013) reviewed mesenchymal stem cells, they discovered 72 preclinical and 18 clinical papers, the 18 clinical publications included none randomized, five comparative, six case series, and seven case reports, two clinical studies used MSCs from adipose tissue, five from bone marrow concentrate, and 11 from bone marrow, despite rising interest, preclinical and low-quality clinical studies suggests knowledge of this molecular mechanism for cartilage regeneration is still limited, mSC source may alter results, although the evidence utilizes many sources and is unclear, this biological cartilage repair approach needs randomized controlled studies to assess its efficacy and contrast with existing therapies, critical evidence per MSC source for product equivalentity question.

Wong (2013) cultivated MSCs in 56 osteoarthritis patients with medial opening-wedge high tibial osteotomy and cartilage lesion microfracture, microfracture collected bone marrow and cultured MSCs, after 3 weeks, the cells were viability-tested and delivered to the clinic for intra-articular injection of MSCs suspended in HA or HA alone for controls, the major outcome was the six-month, one-year, and two-year IKDC score, two-year Tegner and Lysholm and one-year MRI MOCART scores were secondary outcomes, all patients completed two-year follow-up, the MSC-treated group scored considerably higher on the IKDC, Lysholm, and Tegner after correcting for age, baseline scores, and assessment time (mean difference 7.65 on 0 to 100 scale, p=0.001), 7.61, and 0.64, respectively, blinded MRI showed MSCs had higher MOCART scores, more MSC-treated individuals had comprehensive cartilage coverage of their lesions (32% vs 0%), more than 50% (36% vs 14%), and full integration of the regenerated cartilage (61% vs 14%), in a double-blind, controlled trial, 47 radiographic and symptomatic knee osteoarthritis patients participated, selected intra-articular injections included autologous bone marrow-derived culture-expanded MSCs (n=16), MSCs with PRP (n=14), and corticosteroid (n=17), mSCs raise Knee Injury and Osteoarthritis Outcome Score (KOOS) after one month (p=0.003) and both MSCs and MSCS + PRP improve best after one year.

Vega (2015) randomised 30 patients with chronic knee pain unresponsive to conservative treatments and radiographic arthritis to a small RCT on bone marrow-derived MSCs for knee osteoarthritis, in an intra-articular injection, 15 patients received allogeneic bone marrow MSCs and 15 controls received hyaluronic acid, a year-long clinical outcome study evaluated pain, disability, and life

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

quality, qMRI T2 mapping assessed cartilage, the MSC-treated patients exhibited considerably improved algofunctional markers than the active controls, t2 relaxation tests showed higher cartilage quality in MSC-treated individuals, reducing poor cartilage sites.

Two Korean labs have not reported on adipose-derived MSCs for cartilage regeneration, for years, one group has offered this treatment and just published an RCT on cartilage regeneration after high tibial osteotomy (HTO) in 52 medial compartment osteoarthritis patients, randomly, patients got HTO with PRP or PRP with MSCs, buttock liposuction produced adipose MSCs, censoring tissue mixed stromal vascular fraction with PRP for injection. 44 patients had second-look arthroscopy and one- and two-year clinical follow-up, pRP alone and PRP+MSC results differed significantly in Knee Injury and Osteoarthritis Outcome Score (KOOS) subscales for pain (74±5.7 vs. 81.2±6.9, p<0.001) and symptoms (75.4±8.5 vs. 82.8±7.2, and Pain ratings differed substantially between PRP alone and PRP+MSC groups (16.2±4.6 vs. 10.2±5.7, p<0.001), although Lysholm scores did not alter (80.6±13.5 vs. 84.7±16.2, p=0.36), video examination of second-look arthroscopy indicated MSCs accelerated articular cartilage regeneration, although blinding is unclear, the small sample size, short follow-up, and significant improvements on just a few outcomes limit this study, the therapeutic significance of the data is uncertain since all significant outcomes changes were minor.

They compared adipose-derived MSCs, fibrin glue, and microfracture to microfracture alone, symptomatic femoral condyle cartilage lesions were grade III/IV in 80 participants randomized to the interventions, the average follow-up was 27.4 months, the MSC + fibrin glue + microfracture group improved Knee Injury and Osteoarthritis Outcome Score pain and symptom subscores more than microfracture alone (p=0.034 and 0.005) at follow-up, daily living, sports and recreation, and quality of life subscores were comparable among groups, second-look arthroscopies (57 of 80) were similar across groups, without blinding, this study's results are restricted, the Zaffagnini (2022) RCT assessed 118 knee OA patients' single intra-articular injection of microfragmented adipose tissue or PRP, main outcomes were 6-month IKDC subjective score and KOOS pain subscore, both therapy dramatically improved clinical outcomes from baseline, with no significant differences, from baseline to 6 months, IKDC scores (from 41.1 ± 16.3 to 57.3 ± 18.8 with microfragmented adipose tissue and from 44.8 ± 17.3 to 58.4 ± 18.1 with PRP) and KOOS pain subscore (from 58.4 ± 15.9 to 75.8 ± 17.4 with microfragmented tissue and 63.5 ± 17.8 to 75.5 ± 16.1 with PRP) significantly improved, a secondary study demonstrated that more microfragmented adipose tissue patients with moderate/severe knee OA had the least clinically relevant IKDC score decrease at 6 months than the PRP group (75.0% vs 34.6%, respectively; p=.005), symptomatic knee osteoarthritis adults enrolled in a multisite prospective double-blinded placebo-controlled clinical trial, for intra-articular progenitor and mesenchymal stem cell injection from adipose tissue, 39 eligible patients received high-dose, low-dose, or placebo liposuction stromal vascular fraction medium, wOMAC score change after six months was 83.9%, 51.5%, and 25.0%; after one year, 89.5%, 68.2%, and 0%, after six months (high dose, p=0.04; low dose, p=0.02) and one year (high dose, p=0.006; low dose, p=0.009), osteoarthritis symptoms and pain decreased dosage-dependently compared to placebo.

A 2013 small randomized controlled trial employed autologous peripheral blood MSCs for localized articular cartilage abnormalities, fifty knee patients with grade 3 and 4 lesions underwent arthroscopic subchondral drilling and five weekly HA injections, randomization assigned peripheral blood stem cell injections or no treatment to half the patients, the treatment group averaged 38 years old and the control group 42, splitting and cryopreserving peripheral blood stem cells activated with recombinant human granulocyte colony stimulating factor, repeated HA and MSC three times a week following surgery, the MSC group had a 10% higher histology score (1,066 vs. 957 by independent observers) and a morphologic score (9.9 vs. 8.5) at 18 months following surgery after second look arthroscopy on 16 patients in each group, both groups had comparable IKDC scores 24 months after surgery, baseline patient age may alter subchondral drilling response.

Akgun (2015) performed a small (n=14) investigator-blinded RCT comparing matrix-induced autologous synovial tissue MSCs versus chondrocyte implantation, two days on a collagen membrane, arthroscopically acquired cartilage chondrocytes and synovia MSCs grew, the cells faced subchondral bone during implantation, after surgery, evaluations

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

lasted 24 months, the MSC group outperformed the MACI group on KOOS subscales and VAS pain score at six months ($p<0.05$), however the therapeutic significance of this difference is unclear, this treatment's long-term consequences need more samples and histology.

Lim (2021) examined 114 patients with significant, full-thickness cartilage defects (International Cartilage Repair Society grade 4) who underwent microfracture or MSC-HA in an RCT, study included 48-week phase 3 clinical trial and 5-year follow-up (64%). 89 of 114 randomized participants completed the phase 3 study (78.1%) and 73 joined the follow-up (64.0%), the primary outcome, proportion of participants with cartilage restoration equivalent to at least 1 grade improvement on the ICRS Macroscopic Cartilage Repair Assessment at 48-week arthroscopic evaluation, was 97.7% (42/43) in the MSC-HA group and 71.7% (33/46) in the microfracture group (odds ratio, 16.55; 95% CI, 2.06 to 133.03 At 48 weeks, both groups had considerably better VAS pain, WOMAC, and IKDC scores compared to baseline, however there was no significant difference, the MSC-HA group sustained substantial improvements from baseline from 36 to 60 months following intervention, but the microfracture group decreased in VAS pain and WOMAC, this study has flaws, no intervention group got MSC alone, microfracture is not the standard of care for large, full-thickness cartilage lesions, surgeons and volunteers were not blinded to treatment outcome, and data loss was substantial, this population needs further RCTs to determine the efficacy of umbilical cord blood-derived MSCs, at 48 weeks, the intervention group did not enhance patient outcomes.

In 2014, Vangsness performed a phase 1/2 randomized, double-blind, multicenter study on injecting cultured allogeneic MSCs (Chondrogen™, Osiris Therapeutics) into the knee following partial men The trial randomized 55 patients to receive intra-articular injections of 50´106, 150´106, or HA vehicle control 7-10 days post-meniscectomy, unrelated donor bone marrow aspirates cultivated MSCs, three low-dose MSC patients had significantly increased meniscal volume by MRI at two years, compared to none in the control or high-dose groups, there were no significant Lysholm Knee Scale variations across groups, mSC-treated osteoarthritis patients had much less pain at two years than those who received HA alone, this analysis looks tentative and post-hoc, investigatory treatment had no serious side effects.

4.3.Research Significance

Within the framework of orthopedic medicine, study on stem cell use is quite important, study on mesenchymal stromal cells (MSCs) and bone marrow concentrate (BMC) have shown how well they may solve problems such bone fractures, deformities, and non-unions in orthopedic surgery (Eder et al, 2020), promising in their ability to interact with other cells in vivo, induce differentiation, and affect the human immune system, MSCs help to facilitate healing via these means, furthermore under discussion in orthopedic uses worldwide are derivatives of adipose tissue, such as stromal vascular fraction (SVF) and adipose-derived stem/stromal cells (ADSCs). (Ossendorff et al, 2023) underline the requirement of thorough quality control of publications to ascertain the scientific validity and resilience of study works in this field, these results highlight the possible contributions of stem cell study to improving orthopedic therapies and patient outcomes, therefore demonstrating the significance of such study in the framework of present clinical practices and future lines of exploration, advancement of scientific knowledge and guarantee of the validity of study studies depend on the assessment of methodologic quality and worldwide dissemination of studies exploring the use of stem cells in orthopedics.

4.5.Research Objectives

Within the framework of stem cell application in orthopedic surgery, the guiding principle for the methodical study and meta-analysis is much influenced by study aims, clearly defining the objectives of the study will help to guide the thorough investigation of stem cell treatment in orthopedic uses, particularly, the goals could be evaluating the efficacy of mesenchymal stromal cell and bone marrow concentrate treatments for musculoskeletal indications, analyzing clinical trials using mesenchymal stem cells in orthopedic diseases, and assessing possible sources and fields of application for mesenchymal stem cells in orthopedic surgery (Eder et al, 2020), furthermore, the study aims to find methodological errors in meta-analyses of clinical studies on the management of knee osteoarthritis with stem cells as well as to compile thorough data on the treatment of knee osteoarthritis with various stem cell types by means of a systematic review of the literature (Schmitz et al, 2022), these study goals are essential in giving the methodical

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

study and meta-analysis a clear direction, so ensuring that the study is targeted and deliberate and that the resultant analysis is thorough and perceptive, so advancing orthopedic medicine.

4.2.Meta-Analysis Methodology

With reference to Ossendorff et al, (2023) who conducted a comprehensive systematic review to enhance the reliability and comprehensiveness of the meta-analysis, they utilized electronic databases extensively to identify all pertinent publications and incorporate them, as Schmitz et al, (2022) have noted, it is essential to assess the quality of publications in orthopedic medicine and stem cell study to enhance scientific comprehension and practical application.

5.Clinical Trials and Evidence

Extensive study has been directed on clinical trials and data on the use of stem cells in orthopedic surgery, Eder et al, conducted a systematic review of clinical studies using mesenchymal stromal cells (MSCs) in orthopedic conditions to show the potential of MSCs in contributing to healing by differentiation, secretion of particular factors, and interaction with other cells in vivo, the study clarified the efficiency of MSC treatments in treating orthopedic disorders by including results of patients with aseptic loosening of total hip arthroplasty and concomitant bony abnormalities (Eder et al, 2020), furthermore, Schmitz et al, performed a methodical study pointing out methodological errors in meta-analyses of clinical trials on stem cell-based knee osteoarthritis treatment, emphasizing the requirement of thorough technique in evaluating the results of stem cell treatments, the study included sub-analyses contrasting many stem cell treatments with placebo interventions, in the area of orthopedic surgery, this emphasizes the need of closely reviewing the data from clinical studies to guarantee the correctness and dependability of conclusions (Schmitz et al, 2022), using stem cells, that can differentiate into many cell types, to treat orthopedic and musculoskeletal ailments is growing, embryonic, mesenchymal, and hematopoietic stem cells exist, adult bone marrow separates mesenchymal and hematopoietic stem cells, whereas embryonic tissue isolates embryonic stem cells, some stem cells may become several cell types, whereas others are confined to a few lineages, hSC transplantation is the only clinically validated stem cell therapy (Gepstein, Skorecki, 2020), according to America, after age, sickness, injury, or congenital flaws, regenerative medicine produces living, working tissues to repair or restore tissue or organ function, according to the NIH (2010), cellular therapies stimulate local cell proliferation and differentiation for regeneration, stem cells modulate paracrine and immunological processes by producing growth factors and cytokines, stem cells should protect cells and restore tissue by preventing pro-inflammatory cytokines, orthopaedic mesenchymal stem cells arise from bone marrow, lipoaspirate, umbilical cord tissue, amniotic fluid, and other extra-articular sources, adult-derived, undifferentiated, multipotent mesenchymal stem cells (MSCs) express many cell surface proteins and may become adipogenic, osteogenic, or chondrogenic, adult MSCs cannot become pluripotent, therefore they can develop into all embryo germ layer cell types, normal bone, cartilage, and adipose tissue grow from MSCs, all mesenchymal tissues—muscle, tendon, and fibrous—should have this, mSCs cannot become brain or liver cells (Cook, Young, 2022), mSCs are immunosuppressive, therefore hosts accept them, benefits of autologous MSCs include in vitro isolation, growth, and therapy, autologous and allogenic MSCs cure orthopedic disorders, incubating or condensing MSCs for direct injection is possible, however the optimal quantity to transplant/seeded is unclear, after culture, MSCs may be planted onto scaffolds or mixed with gels or pastes, study has examined seeded scaffolds for bone and cartilage repair, however, stem cells may turn malignant (Wang, et al, 2012), and autologous MSCs can affect cancer cell behavior and accelerate tumor formation, whereas allogeneic MSCs may raise infection risk, extraction, isolation, and culture of MSCs from bone marrow or lipoaspirate are required, cryopreserve MSCs following proliferation, other manufacturing techniques may avoid cellular separation and proliferation (nonexpanded cells), although stem cell content is unknown, researchers are also studying autologous stromal vascular fraction (SVF) as adipose-derived stem cells for osteoarthritis repair, sVF comprises nucleated adipose tissue stromal and vascular cells, sVF does not need cell growth or culture (Garza, et al, 2020), for orthopedic and musculoskeletal disorders, peer-reviewed medical literature advises pharmaceuticals, weight reduction, physical therapy and exercise, acupuncture, chiropractic treatment, and surgery when all else fails, some patients may avoid knee arthroplasty using stem cell therapy, a new treatment, cigna Medical Coverage Policy 0118 Bone Graft Substitutes and 0507 Autologous Platelet-Derived

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

Growth Factors (PRP) for orthopedic Use discuss demineralized bone matrix (DBM) and other stem cell-based bone repair treatments.

5.1.Key Studies and Findings

Important study efforts have been directed on key studies and results on the use of stem cells in orthopedic medicine, by means of a thorough assessment of the present literature, (Eder et al, 2020) found 119 relevant articles on mesenchymal stromal cell and bone marrow concentrate treatments for musculoskeletal reasons, clinical investigations and trials proving the possible use of mesenchymal stem cells (MSCs) in orthopedic conditions including bone fractures, deformities, and non-unions made up the review, (Ossendorff et al, 2023) systematically reviewed the worldwide distribution of studies on the use of adipose tissue derivatives in orthopedics, the evaluation sought to evaluate the quality of these investigations and provide details on the items that were on hand, to establish the scientific validity and robustness of publications, the authors underlined the need of assessing their methodologic quality, their methodical analysis of randomized controlled trials, prospective cohort studies, and retrospective comparative trials helped to clarify the many spectrum of clinical investigations using adipose-derived stem/stromal cells (ADSCs) or stromal vascular fraction (SVF) in orthopedic uses, this paper offers a useful summary of the present evidence and uses of adipose-derived stem cells and stromal vascular fraction in orthopedic medicine, therefore clarifying the quality and distribution of study in this subject, areas undergoing current investigation for the application of MSCs include but are not limited to regeneration and/or repair of musculoskeletal tissue, for example muscle, ligament, tendon, meniscus repair (Rinonapoli, et al, 2021; Centeno, et al, 2018a; Chew, et al, 2017; Lin, et al, 2017; Pas, et al, 2017b; Matsukura, et al, 2014; Centeno, et al, 2015; Vangsness, et al,,2014); treatment of joint disease, including, cartilage lesions, degenerative joint disease, and joint capsular injury (Ha, et al, 2019; Park, et al, 2017; Lee, Wang, 2017; Goldberg, et al, 2017; Filardo, et al, 2013; Ganjii, Hauzeur, 2009); osteoarthritis of the knee, hip, ankle, and shoulder (Wiggers, et al, 2021, Natali, et al, 2021; Garza, et al, 2020; Prodromos, et al, 2020; Simunec, et al, 2020; Lee, et al, 2019; Delanois, et al, 2019; Migliorini, et al, 2019; Emadedin, et al, 2018; Jevotovsky, et al, 2018; Centeno, et al, 2018b; Vannabouathong, et al, 2018; Pas, et al, 2017a; Cui, et al, 2016; Burke, et al, 2016; Vega, et al, 2015; Centeno, et al, 2014; Mobasheri, et al, 2014; Koh, et al, 2013; Pak, 2011); epicondylitis (Ahmad, et al, 2012); fracture (Yi, et al, 2022), including nonunion (Centeno, et al, 2011); and various spinal conditions such as spinal cord injury and intervertebral disc repair (Khan, et al, 2017), the peer-reviewed scientific literature on MSCs for various disorders includes preliminary animal studies, case reports, case series, nonrandomized comparative trials, systematic reviews/meta-analyses, and a few randomized trials, study on MSCs are challenging to ascribe exclusively to treatment responses because to varying stem cell and extraction procedures, limited sample sizes, and effects lasting < two years, some study also utilize hyaluronan or platelet-rich plasma, well-designed, controlled studies have not demonstrated regeneration, tissue remodeling, extraction, concentration, infusion, indications, ideal MSC source, and cell amount, mSCs for orthopedic and musculoskeletal illnesses need longer RCTs to verify their safety and efficacy, mSC therapies' clinical benefits have not yet offset their risks, several clinical trials using MSCs for osteoarthritis, tendon regeneration, and other orthopaedic problems are ongoing, according to the NIH website, these studies treat orthopedic and musculoskeletal illnesses using expanded and nonexpanded MSCs.

Meniscus healing is poor, animal studies have employed stem cells to treat meniscal injuries, but few human research, mechanical properties and extracellular matrix differ from normal meniscal tissue (Chew, et al, 2017), after meniscal injury, synovial fluid contains MSCs (Matsukura, et al, 2014), synovial fluid with meniscus injury contains more MSCs than normal knees, the authors speculated that MSCs in synovial fluid facilitated spontaneous meniscus repair and that further study is needed to determine whether higher MSC levels enhance healing, mSCs may repair meniscal injury by intraarticular injection or local delivery using a seeded scaffold (tissue engineering technique), although clinical trials are limited, few participants, and short-term, a 2021 systematic review analyzed pre-clinical (n=13) and clinical (n=5; two case controls, one case report, one RCT, and one case series) stem cell meniscal repair studies, injection is the most explored and promising cell source and delivery method, however evidence is inadequate to determine, they noted that therapeutic benefit required more study and better trials, in 2014, Vangsness et al, randomized 55 patients undergoing

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

partial medial meniscectomy across seven facilities into three treatment groups: Group A (50×10^6 allogeneic mesenchymal stem cells injection), Group B (150×10^6 injection), and the control group (sodium hyaluronate/hyaluronan vehicle control), injections of ex vivo MSCs occurred 7–10 days following surgery, the two-year clinical outcomes included safety, meniscal regeneration, and knee joint condition, vAS and Lysholm knee scales assessed pain, mSC injections substantially decreased VAS pain compared to controls, group A included 24% (3 patients) with a >15% increase in meniscal volume after two years, indicating MRI-detected tissue regeneration, there were 427 adverse events: 272 mild, 126 moderate, 28 severe, and one life-threatening (heart attack one year after surgery), arthralgia, swelling, stiffness, injection-site joint pain, effusion, headache, and peripheral edema were the most common adverse effects, therapy was unlikely to have major side effects, authors say a limited sample size, MRI scan inconsistencies across facilities, and lack of osteoarthritis control between groups limit the findings.

6.Challenges and Limitations

The effective use of stem cell treatment depends on addressing various difficulties and restrictions related to their usage in orthopedic care, managing more significant bone deformities, non-unions, and delayed unions after inadequate healing of fractures is one of the main difficulties, this is still a major problem in orthopedic surgery; mesenchymal stromal cells (MSCs) have showed promise in helping the healing process because of their differentiation capacity and release of certain elements influencing the human immune system, mSCs also have the ability to interact with other cells in vivo, hence improving their potential use in orthopedic treatment (Eder et al, 2020), in orthopedic surgery the treatment of bone abnormalities, non-unions, and delayed unions still presents a great difficulty, particularly those utilizing mesenchymal stromal cells (BMDSCs) generated from bone marrow, stem cell treatments have shown encouraging outcomes in improving bone production, raising bone mineral density, and treating nonunion events, using BMDSCs for traumatic spinal cord injuries has also shown successful results, suggesting the possibility of stem cell treatment in treating severe neurological damage (Akpancar et al, 2016), these results underline the possibilities of stem cells in orthopedic treatment and the need of overcoming their related difficulties.

6.1.Ethical Considerations

Stem cells used in orthopedic surgery bring significant ethical questions that have to be properly resolved, bone marrow concentrate (BMC) and mesenchymal stromal cell (MSC) treatments in particular have promise for treating musculoskeletal diseases including bone deformities, non-unions, and aseptic loosening of total hip arthroplasty., still, it is impossible to ignore the ethical ramifications of employing stem cells, moral, legal, and social ones as well as others (Eder et al, 2020), the moral issues related to the therapeutic use of stem cells are many and complicated, each of the embryonic, fetal, and adult stem cells—each having ethical issues, should be categorized under this heading, furthermore underlined by the possible hazards connected with employing embryonic stem cells, like teratoma development and immunological responses, are the necessity of thorough ethical debate (Hui et al, 2009), furthermore, the creation of individualized pluripotent stem cells and the availability of autologous stem cells such as MSCs from bone marrow provide both possibilities and difficulties in the ethical terrain of orthopedic stem cell treatment, these ethical issues are very important in directing the appropriate and efficient use of stem cells in orthopedic surgery.

6.2.Technical Hurdles

Stem cells used in orthopedic medicine create various technological challenges that must be resolved if successful use is to result, stem cells' isolation and growth are one such difficulty, orth et al, (2014) demonstrated the therapeutic potential of bone marrow-derived mesenchymal stem cells (BMSCs) and adipose-derived stem cells (ASCs) in knee cartilage regeneration, therefore highlighting their efficacy, crucially technological challenges that need to be addressed are also preservation and storage of stem cells as well as the development of suitable delivery and monitoring techniques for stem cell-based therapeutics (Orth et al, 2014), moreover, the requirement of fresh approaches to hasten fracture healing, especially in patients with comorbidities or complex fractures, has spurred study on stem cell treatments (Akpancar et al, 2016), successful integration of stem cell treatments in orthopedic medicine and enhancement of patient outcomes depend on addressing these technological challenges.

7.Literature Review

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

The authors of this section, with reference to 2020's Eder et al, who assessed orthopedic studies, conducted a thorough analysis of the utilization of stem cells in orthopedic medicine, specifically focusing on the applications of bone marrow concentrate (BMC) and mesenchymal stem cells (MSCs) in musculoskeletal conditions, the review emphasized the role of MSCs in differentiating and secreting specific elements that impact the human immune system, the authors also emphasized the potential of MSCs in addressing challenges such as large bone defects, non-unions, and delayed unions after fractures, the review's objective was to assess the quality of the study and provide information on the available options, the authors conducted a comprehensive analysis to examine the global distribution of studies that investigated the use of various types of fat tissue in orthopedics (Ossendorff et al, 2023), the analysis emphasized the importance of conducting rigorous clinical trials and utilizing appropriate study techniques to ensure meaningful and reliable outcomes in the field of adipose-derived stem/stromal cells (ADSCs) or stromal vascular fraction (SVF), the review was designed to evaluate the methodological quality of publications, excluding reviews, meta-analyses, and animal or in vitro studies, in order to identify pertinent papers, the authors implemented predetermined eligibility and inclusion criteria, that included retrospective comparative trials, prospective cohort studies, and randomized controlled trials, osteonecrosis destroys bone tissue via vascular malfunction, femoral head osteonecrosis collapses and replaces the hip, for femoral head preservation, medical literature recommends implanting stem cells into osteonecrosis-related hip necrotic lesions, however, early injectable cell treatment experiments have not showed bone repair, li and colleagues did a meta-analysis of stem cell treatment with core decompression and biomechanical support for femoral head osteonecrosis, the study covers 10 RCTs with 498 participants and 719 hips, most RCTs were low-quality, had small samples (n=18-125), and had short followup (2-3 years), stem cell sources and numbers vary per investigation, vAS, Harris hip score, and adverse events assessed clinical outcomes, we found no publication bias and varied outcome indicators, the review revealed substantial differences in Harris hip score and VAS compared to the control group, indicating a preference for stem cell therapy for pain relief (MD=8.87, 95% CI, [P<0.00001]; MD=-14.07, 05% CI, [P<0.000 Adverse events were comparable across groups, despite low problems, stem cell combination with core decompression needs high-quality, large-sample, multicenter long-term RCTS to confirm safety and efficacy (Li, et al, 2021), a comprehensive Andronic et al, (2021) study compared biologic augmentation with core decompression to core decompression alone for femoral head osteonecrosis, ten trials enhanced 560 hips (484 patients) using bone marrow stem cells, platelet-rich plasma, or BMP, only four augmentation studies improved all clinical ratings, seven reduced radiographic progression, and five reduced total hip arthroplasty conversion, the authors say biologic augmentation to core decompression for osteonecrosis is uncertain, pak released 2011 case reports on adipose-derived MSCs' bone healing in human osteonecrosis, the study injected adipose MSCs with hyaluronic acid, platelet-rich plasma, and calcium chloride into two osteonecrotic hips and knees, to verify MSCs produced regeneration, MRI data indicated bone and cartilage formation three months after treatment.

Most orthopedic stem cell study focuses on knee osteoarthritis cartilage repair, even without adjuvant treatment, injecting stem cells directly into the defect or planting them on a scaffold offers mechanical support, subchondral bone marrow MSCs and scaffolds may improve joint pain, survival, and surgery (Hernigou, et al, 2021), kim et al, (2022) ran an RCT comparing intra-articular injection of ADMSC after medial open-wedge high tibial osteotomy (MOWHTO) (n=13) to MOWHTO, we monitored participants for 24 months, periodic MRI examinations with reliable measurements showed cartilage defect serial alterations till 24 months postoperatively, secondary results included postoperative functional improvements and two-stage arthroscopic macroscopic articular cartilage evaluation, serial MRIs (69.2%) and arthroscopic inspection (23.1%) demonstrated that the experimental group had significantly more cartilage regeneration than the high-tibial osteotomy group at 24 months, despite not being statistically significant, stem cell patients exhibited greater functional improvements 18 months after therapy, scientists believe adipose-derived mesenchymal stem cell injections may safely treat knee osteoarthritis, short-term outcomes and small sample size are limitations, the Zhang and colleagues (2022) RCT compared stromal vascular fraction injection (n=56) to hyaluronic acid injection (n=70) for knee osteoarthritis, participants required to meet the

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

American Rheumatism Association Revised Classification Criteria for Knee Osteoarthritis, Kellgren–Lawrence (KL) grade 2–3, age 20–85, and no serious trauma, divided randomly into SVF or hyaluronic acid groups, three months of monthly injections, vAS and WOMAC ratings measured pain and function for 1, 2, 3, and 5 years, mRIs examined medial and lateral tibia, femur, patella cartilage structure and volume and bone marrow lesions, surgery to treat knee osteoarthritis failed, treatment comprised 51 patients and control 64 at five years, the therapy group's VAS and WOMAC ratings were lowest after one year, rose annually, and remained lower after five years, at 1 year, the control group's VAS and WOMAC scores were identical to pretreatment, then rose annually and were much higher at 5 years, we examined both groups' Kaplan–Meier response curves for all patients, at 5-year follow-up, SVF had 62.5% (35/56) responsiveness and HA 20% (14/70), despite having less cartilage volume after five years, the therapy group had more, and a few patients who received stromal vascular fraction showed full-thickness cartilage defect healing, marrow lesion size, severity, patella-femoral pathology, and mechanical axis did not vary across groups from baseline to 5 years, the Kaplan-Meier analysis included nine surgical patients (3 SVF and 6 HA), but not the comparison study, the trial's lack of a targeted lesion injection and exclusion of KL Grade 4 participants prevent the authors from determining cell destination or efficacy, a 2021 RCT by Wong and colleagues assessed intra-articular cultured autologous bone-marrow-derived MSC injections, microfracture, and medial opening-wedge high-tibital osteotomy for unicompartmental arthritis, randomly allocating 56 individuals to cell-recipient (n=28) or control (n=28) groups, three weeks following surgery, the cell recipient group received MSCs and hyaluronic acid whereas the control group received acid, patients under 55 with medial-compartment OA, genu varum diagnosed arthroscopically and/or radiographically, normal lateral joint space, no fixed knee flexion deformity, and no collateral ligament instability were eligible, age above 55, femoral knee malalignment, fixed flexion deformity, and joint line congruity angle more than 2 excluded, use the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scoring method to assess cartilage regeneration at six months, one year, and two years following therapy using Tegner and Lysholm scores, IKDC scores, and MRI, the authors claimed they would monitor patients for 5-10 years, the trial showed that cell recipients had higher Tegner, Lysholm, and IKDC scores, cell recipients' MOCART scores increased significantly on MRIs, lack of blinding and short-term follow-up are trial drawbacks, several meta-analyses have examined knee osteoarthritis therapy with MSCs alone (Tan, et al, 2021; Ma, et al, 2020; Prodromos, et al, 2020), MSCs/stromal vascular fractions, or MSCs plus additional biologic agents, these studies overlap, but intra-articular MSC injection improves pain and function, kim and colleagues (2021) compared intra-articular injections of autologous adipose-derived mesenchymal stem cells (ASCs) or ADSVFs without adjuvant therapies to placebo or hyaluronic acid in knee osteoarthritis patients in a comprehensive analysis of five RCT VAS and WOMAC assessed pain relief and function, assessing cartilage health with MRI, one RCT followed up at 6 months, the others at 12 months, the meta analysis showed that ASCs or ADSVFs provided greater pain alleviation and functional improvement at 6 and 12 months, while not affecting procedure-related knee discomfort or swelling compared to controls ($Z = 7.62$; $P<.0001$, $Z = 7.21$; $P<.0001$, $Z = 4.13$; $P<.0001$, $Z = 3.79$; $P = .000$ A meta-analysis was unable due to variable MRI examination, however three studies showed significantly improved cartilage following injection, few studies, small sample sizes, changing cell concentrations, and short-term follow-up restrict the review.

Tan et al, (2021) analyzed 19 Level 1 and 2 intra-articular MSC injection trials without adjuvant treatment with a mean follow-up of 11.9 months, only MSC source and culture status influenced treatment outcome clinically and statistically, compared to adipose MSCs, bone marrow MSCs reduced pain VAS by 1.50 and WOMAC by 23.2, cultured MSCs reduced VAS and WOMAC ratings, the authors noted limitations in evidence quality (1 and 2) and appropriately powered trials, follow-up (3–48 months, average 11.9 months), and data pooling, that may have introduced confounders not accounted for in the original research, anil et al, (2021) did a network meta-analysis of RCTs on knee osteoarthritis intra-articular injections of autologous conditioned serum, bone marrow aspirate, botulinum toxin, corticosteroids, hyaluronic acid, MSCs, ozone, saline, PRP, plasma rich growth factor, The study covers 8761 people from 79 RCTS, vAS and WOMAC tested at 1, 3, 6, and 12 months, frequentist analysis contrasted clinical outcomes and P-score placed treatments, response took four weeks to 24

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

months, in all post-injection times, SVF exhibited the highest VAS P-score (0.8922–99230), at 12-months post-injection, SVF patients had the highest functional outcome ratings and WOMAC scores (P-score = 0.9034), most SVF harvests used collagenase to separate adipose, that is FDA-prohibited in the US, sVF must be manually separated from adipose tissue in the US, the authors admit a lack of trial data and post-operative outcome indicators, sVF collection and separation may alter treatment effectiveness, ma et al, (2020) examined 10 RCTs and found that intra articular MSC injections temporarily lowered VAS ratings and improved WOMAC scores, studies included 6-12 month follow-up, although not significant, the MSC group had somewhat more cartilage volume than the control group, that the scientists think slows cartilage degeneration, the review's limitations include the use of different MSCs, control group heterogeneity (hyaluronic acid in five studies, a placebo in four, and conservative management in one), advanced Kellgren–Lawrence Grade 4 OA in some subjects, and incomplete data in some studies that led to attrition bias, this extensive study by Prodromos et al, (2020) examined autologous mesenchymal stem cell therapy for knee osteoarthritis, group I comprised WOMAC and VAS score results (n=29), Group 2 included various techniques (n=5), and Group 3 included randomized trials with 1-3 saline injections as a placebo (n=18), study used adipose-derived stem cells, stromal vascular fraction, bone marrow aspirate, culture-expanded bone marrow, and minimally modified fat grafts, after treatment, follow-up averaged 14.4 months and lasted six to five years, after six months and final followup, all Group I trials exhibited significant WOMAC and VAS improvements above the clinically relevant difference, group 2 scores rose significantly from baseline to final followup, no dose-response relationship between cell dosage and outcome, garza and colleagues (2020) compared intra-articular stromal vascular fraction (SVF) to placebo for knee osteoarthritis symptoms in a randomized, controlled, doubly-blind research, sVF relieved pain for 15.3 months longer than corticosteroids, hyaluronan, NSAIDs, and oral analgesics, patients received knee-injected high-dose, low-dose, or placebo SVF, mRI and WOMAC scores at 3, 6, and 12 months post-injection assessed results, six months was the trial's unblinded participants' principal efficacy follow-up, high dose, low dosage, and placebo groups exhibited median WOMAC changes of 83.8%, 51.5%, and 25% at six months and 76.9%, 76.9%, and 46.2% at one year, however, only 26 were available for one-year followup versus 37 at six months, at one year, 23 subjects' MRIs indicated no disease progression or cartilage thickness change, studies revealed SVF injections improved osteoarthritis symptoms after 12 months, unblinding at 6 months, imputed missing data scores, small sample size, and short followup are study limitations. Impact on disease progression needs longer-term evaluation, lee et al, (2019) studied knee osteoarthritis with high-dose autologous adipose-derived MSC injection in a randomized, double-blind placebo-controlled trial, patient selection criteria were Kellgren-Lawrence grade 2–4 knee osteoarthritis, 12-week VAS pain of four or more, and at least one focal or localized grade 3–4 MRI lesion, at one, three, and six months, 12 participants received intra-articular normal saline or adipose MSC injections, mSC injection improved WOMAC (55% reduction), VAS for knee soreness, and range of motion after six months, no improvement in control group results, at six months, MRI indicated no cartilage defect change in the treated group but an increase in the control group, the scientists reported satisfactory function and pain relief after six months, but larger studies are needed to prove therapeutic efficacy, a systematic review by Pas et al, (2017a) studied knee osteoarthritis stem cell injections, one non-RCT and five RCTs met review criteria, we included published and unpublished studies, participants with any degree of knee osteoarthritis, stem cells of any origin compared to any other intervention, minimum stem cell count/typing, patient-reported pain, imaging grading system, and adverse events, no time, language, or content restrictions, all studies used bone-marrow, adipose, or peripheral blood stem cells, all studies injected 15–36 stem cells into 15–36 patients, whereas 155 were controls, one experiment gave eight MSC injections, whereas five gave one, five RCTs injected MSCs with PRP and/or HA, controls got HA and PRP alone, two tests used uncultured MSCs, strong bias in all trials yielded level-3 evidence, the Visual Analogue Scale, Western Ontario and McMaster Universities Arthritis Index, Tegner, Lysholm, International Knee Documentation Committee, Knee Injury and Osteoarthritis Outcome Score, and Lequesne showed that all five RCTs outperformed controls at 24–48 months, no big problems occurred, radiological outcomes improved after stem cell infusion, knee OA stem cell infusions lack proof and are unwise.

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

In 2016, Cui and colleagues published a meta-analysis of osteoarthritis stem cell therapy. 10 single-arm prospective studies (5-41), 4 quasi-experimental studies (18-56), and 4 RCTs (50-56) met the inclusion criteria, bone marrow, adipose, or peripheral blood stem cells activated by collagen matrix, adipose tissue, or platelet-rich plasma were MSCs, several studies followed up for three to 24 months. IKDC, VAS, Tegner and Lysholm, and WOMAC scores were outcomes, with a pooled effect size of 1.81 relative to pretreatment and all prior follow-up higher, MSC therapy decreased pain and enhanced function at 24 months, therapy MSC quantity was uncertain for dose response, with just RCT data, MSC treatment was not superior, seven studies reported transient localized soreness and edema as the most prevalent adverse effects, and no one acquired cancer following MSC therapy, limitations include the study's small sample size, absence of long-term follow-up, and various MSC doses and activation agents, vega et al, (2015) reported knee osteoarthritis RCT results using bone marrow-derived MSCs, all patients had chronic knee pain and conservative therapy failure, the control group (n=15) received intra-articular hyaluronic acid, whereas the experimental group received allogenic bone marrow-derived MSCs, over one year, pain, disability, quality of life, and cartilage quality MRIs were clinical outcomes, at one year, the treatment group had stronger cartilage and reduced pain, at 6 and 12 months, MSC-treated patients improved significantly, the researchers observed that autologous adipose-derived MSCs were similar while bone marrow-derived MSCs were smaller, small sample size and short-term follow-up impede research, short-term results, lack of controls, various sources and volumes of MSCs, adjuvant treatment in certain studies, and reporting discrepancies restrict MSC therapy's safety and effectiveness, despite accumulating evidence from systematic reviews and meta-analyses, mSC treatments utilized in diverse phases of osteoarthritis, variety in inclusion and exclusion criteria, and lack of long-term results prohibit robust evidence-based judgments on clinical safety and effectiveness, despite short-term pain and function benefits.

Also emerging is stem cell treatment for tendons and ligaments, tendon and ligament regeneration is poor, few studies have used stem cells to heal tendons/ligaments, pas, et al, 2017(b) reviewed stem cell tendon disease therapy, the review included 79 studies—four published and three unpublished/pending, the study studied bone marrow stem cells injected for rotator cuff repair, allogenic adipose-derived stem cells for epicondylar tendinopathy, and patellar tendinopathy, the authors found all trials high-biased and level four evidence, lack of controls limited benefit interpretation, only the adipose-derived stem cell study cultured or typed bone marrow MSCs, ePIC, patellar, and rotator cuff repairs improved healing, function, and discomfort compared to baseline, fewer preoperative stem cell-repaired rotator cuffs ruptured than historical controls or previous articles, only one study found adverse events, safety concerns continue, cell analysis varied across investigations, hence cell dose's effect is unknown, this study deemed stem cell treatment for tendon illnesses unproven, multipotency, paracrine activities, and blood flow improvements make mesenchymal stem cells a promising treatment for rotator cuff disease (Lin, et al, 2017), rotator cuff repairs usually occur at the tendon-bone interface, the tendon often fails to reattach to the bone during healing due to physiological variables, few studies have shown that MSC therapy improves rotator cuff healing.

8.Future Directions

Stem cell study in orthopedic medicine has bright future prospects for developments in therapeutic uses and treatment approaches, further study of mesenchymal stem cells (MSCs) in orthopedic surgery is one possible route, because of their differentiation capacity and release of certain elements influencing the immune system and interacting with other cells in vivo, MSCs have showed promise in bone repair and regeneration (Eder et al, 2020), personalized pluripotent stem cells also pique curiosity in order to solve immunogenicity issues, thereby opening new paths for individualized orthopedic therapy (Hui et al, 2009), with stem cells—especially MSCs—used in treating musculoskeletal conditions like bone fractures, deformities, and non-unions, orthopedic medicine has a bright future, stem cell treatments provide fresh opportunities for rebuilding sick or injured musculoskeletal tissues as study develops, therefore transforming the discipline of orthopedic surgery.

8.1.Emerging Technologies

Emerging methods using stem cells for orthopedic therapy offer great potential to expand available treatment choices, cell culture methods are one of the main developments because they have made mesenchymal stem cells (MSCs) available for

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

therapeutic application expandable, studies on patients with aseptic loosening of total hip arthroplasty and concomitant bone deformities (Eder et al, 2020) have emphasized how MSCs, with their differentiation capacity and release of particular factors, have shown the potential for tissue repair and regeneration, customized scaffolds and improved structural support for directing cell development and tissue healing have also been made possible by genetic engineering and regenerative medicine techniques including 3D printing technologies, biomaterials, and scaffolding, biomaterials, and 3D printing technologies

8.2.Potential Innovations

Stem cell applications for orthopedic medicine have great potential to advance therapies in this discipline, through their differentiation capacity, release of certain factors, and interaction with other cells in vivo (Eder et al, 2020), current study emphasizes the role of mesenchymal stromal cells (MSCs) in helping to recover, using an absorbable sponge as a carrier for autologous bone marrow, a phase IIa clinical study showed, for example, the effectiveness of MSCs in patients with aseptic loosening of total hip arthroplasty and concomitant bony deformities, mSC potential to differentiate into musculoskeletal tissue types also makes them especially suitable for orthopedic use (Hui et al, 2009).

9.Conclusion

Finally, the methodical investigation and meta-analysis on the utilization of stem cells in orthopedic medicine have given important new perspectives on the possibilities of mesenchymal stromal cells (MSCs) and bone marrow concentrate (BM) treatments for musculoskeletal reasons, through their differentiation capacity, production of certain molecules, and interaction with the human immune system and other cells in vivo, the results highlight the major contribution MSCs provide to healing (Eder et al, 2020), furthermore, in patients with aseptic loosening of total hip arthroplasty and concomitant bone deformities, the clinical studies using absorbable sponges as a transporting medium for autologous BM show encouraging outcomes, emphasizing the requirement of strict quality standards in such analyses, the study has also shown the methodological errors in meta-analysis of clinical trials on the treatment of knee osteoarthritis with stem cells (Schmitz et al, 2022), the meta-analysis's independent literature search turned up a significant volume of papers and clinical trials that highlighted the rising interest and study initiatives in the use of stem cells for orthopedic diseases, these results not only provide the present level of knowledge but also indicate directions for further study and practical implementation of stem cell treatment in orthopedic medicine.

9.1.Summary of Key Findings

I summarize hip stem cell study and meta-analysis, the present musculoskeletal study used bone marrow concentrates and mesenchymal stromal cells, the study used 119 studies, clinical trials, review articles, and case series to show that mesenchymal stem cells (MSCs) can treat more severe bone defects, non-unions, and delayed unions caused by fractures, infections, and trauma, the study also showed that MSCs may link with other physiological cells, produce molecules, and affect the immune system, aiding recovery, in addition, a systematic review assessed the quality of study on adipose tissue derivatives in orthopedics, provided product information, and examined global distribution, the review assessed article methodology to ensure scientific validity and study program efficacy, this investigation includes therapeutic case series, prospective cohort studies, and randomized controlled trials, but not reviews, meta-analyses, or expert opinions, human-adipose-derived stem/stromal cells (ADSCs) or stromal vascular fraction (SVF) applications in orthopedic surgery (Ossendorff et al, 2023) showed the importance of thorough study using appropriate methods to produce significant and reliable results.

9.2.Discussion

The implications of the study findings for orthopedic medicine are extensively analysed in the discussion section of the study "The Use of Stem Cells in Orthopedic Medicine: Systematic Study and Meta-Analysis, particularly, the regenerative capabilities of adipose-derived stem/stromal cells (ADSCs) and mesenchymal stromal cells (MSCs) are the focus of the prospective benefits of utilizing stem cells for orthopedic treatments, the discussion also illuminates the constraints associated with the existing methodologies and underscores the necessity of conducting a comprehensive quality assessment of publications in this field to guarantee the scientific validity and robustness of study studies (Eder et al, 2020).

The section offers valuable insights into the direction of future research, underscoring the importance of

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

conducting systematic evaluations to analyze the global distribution of studies investigating the use of stem cells in orthopedics and evaluating methodologic quality, furthermore, it emphasizes the significance of evaluating the quality and furnishing information on available products to facilitate the advancement of scientific knowledge and practical applications in the field of orthopedic medicine (Ossendorff et al,,, 2023).

9.3.Recommendations

Based on the results of the systematic study and meta-analysis, there are numerous suggestions for the application of stem cells in orthopedic medicine, eder et al, (2020) have extensively documented the capacity of mesenchymal stromal cells (MSCs) to facilitate regeneration by means of differentiation, secretion of specific factors, and interaction with other cells in vivo, the literature has also emphasized the successful implementation of stem cell therapy in significant orthopedic procedures, such as osteoarthritis-cartilage defects, bone-joint injuries, ligament-tendon injuries, and osteonecrosis (Akpancar et al, 2016), these results indicate that stem cell therapy, particularly the use of MSCs and bone marrow concentrate, has the potential to be effective in the treatment of a variety of orthopedic conditions.

Further, the integration of scaffolds with stem cells has demonstrated the ability to facilitate quicker and more effective tissue regeneration, particularly in the field of bone tissue engineering, consequently, it is advised that future orthopedic treatment protocols evaluate the potential advantages of integrating scaffolds with stem cell therapy to improve patient outcomes and promote tissue regeneration, these recommendations are predicated on the evidence obtained from the systematic review and meta-analysis of the current literature in the field of orthopedic stem cell therapy.

10. Tables and Appendeces

The Use of Stem Cells in Orthopedic Medicine- Descriptive Research									
Survey Scale: 1=Strongly Disagree 2=Disagree 3=Neutral 4=Agree 5=Strongly Agree									
Question	# 1's	#2's	#3's	#4's	#5's	n	MEAN	MODE	SEM
1, the use of stem cell therapy has the potential to considerably reduce the amount of time that orthopedic patients are required to recover from their injuries while they are undergoing treatment.	17	10	21	29	23	100	3.33	4	***0.2***
2, when compared to the usage of conventional therapies, the transplantation of stem cells has the potential to result in more favorable functional results.	17	8	26	17	32	100	3.35	5	***0.2***
3. I am of the opinion that stem cell therapies are risk-free for use in orthopedic applications.	17	9	31	24	19	100	3.33	3	***0.1***
4. The field of orthopedic surgery need to use stem cell treatment in a more widespread manner.	10	15	17	29	29	100	3.71	5	***0.1***
5. There is a enough amount of scientific data that substantiates the effectiveness of stem cell therapies in field of orthopedics.	9	12	21	30	28	100	3.63	4	***0.1***

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

6. The advantages that stem cell therapies provide in orthopedic surgeries are sufficient to justify the expense of these treatments.	12	9	21	27	31	100	3.60	4	***0.1***
7. In general, patients have a good understanding of the many stem cell therapies that are available in the field of orthopedics.	16	8	21	25	30	100	3.68	5	***0.1***
8. The regulatory criteria for stem cell treatments are sufficient to guarantee the safety of patients under investigation.	14	9	27	24	26	100	3.52	3	***0.1***
9. I am of the opinion that the future developments in stem cell study will bolster the available alternatives for orthopedic therapy.	16	14	26	21	23	100	3.19	3	***0.2***
10. In order for orthopedic surgeons to make successful use of stem cell treatments, they need further training.	9	12	28	28	23	100	3.45	4	***0.1***

The Use of Stem Cells in Orthopedic Medicine-Descriptive Research										
	Q_1	Q_2	Q_3	Q_4	Q_5	Q_6	Q_7	Q_8	Q_9	Q_10
MEAN	3.333	3.347	3.333	3.707	3.627	3.600	3.680	3.520	3.187	3.453
MODE	4.000	5.000	3.000	5.000	4.000	4.000	5.000	3.000	3.000	4.000
StDev	1.300	***1.400***	***1.200***	1.300	***1.200***	***1.200***	***1.200***	1.300	***1.400***	***1.200***
StErr	***0.200***	***0.200***	***0.100***	***0.100***	***0.100***	***0.100***	***0.100***	***0.100***	***0.200***	***0.100***
F	0.568	0.278	0.806	0.337	0.358	0.333	0.004	0.345	0.587	0.258
TTEST	0.768	0.078	0.008	0.198	1.000	0.155	0.845	0.078	0.002	0.001

For this study, according to the findings of the survey, the individuals who participated in the study had a nuanced understanding of stem cell therapy, that indicated that they were both optimistic and skeptical about the procedure, the findings of the study on the utilization of stem cells in orthopedics provide valuable insight into the perspectives of medical professionals regarding this innovative method of injury treatment.

Recovery Time and Functional results: The average scores for questions concerning recovery time (Q1: 3.33) and functional results in contrast to conventional therapy (Q2: 3.35) show that participants had a reasonable agreement that stem cell therapies have the potential to enhance patient outcomes, the yes answer to Q1 indicates that a large proportion of participants believe stem cell therapies are useful in speeding up the healing process, this is consistent with earlier studies showing that stem cells may repair and promote speedier healing in orthopedic patients.

From the statistics, it is clear that a wide variety of viewpoints were taken into consideration, as shown by the standard deviations of 1.30 and 1.40, according to this, even while there are some specialists who are positive about the potential benefits, there are still some who may be cautious or

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

desire further study before completely adopting new therapies, disagreements may occur as a result of varying degrees of information about current developments in stem cell study or as a result of varying experiences in clinical settings.

On Question 3, respondents ranked stem cell therapy's safety and gave it an average score of 3.33, the mode of three indicates that a significant proportion of respondents had mixed feelings about the safety of stem cell applications in orthopaedics, demonstrating their worry about potential risks, that is particularly relevant given the ongoing ethical and regulatory discussions on stem cell t.

An astonishingly high average score of 3.71 for Question 4 indicates a solid confidence in the need of extending the usage of stem cell therapies in orthopedic surgery, this view is supported by considerable scientific facts and is widely accepted, the fact that the respondents gave the fifth question an average score of 3.63 indicates that they have a high level of confidence in the scientific data that supports the efficacy of these treatments and that they seem to be aware of the potential major influence that these therapies may have, Q4 participants are in complete agreement that stem cell therapies need to be used in the medical field on a more widespread scale, as indicated by their median score of 5.

Despite the fact that there is reason for optimism, the existence of standard deviations of about 1.20 suggests that there may be some experts who continue to have misgivings over the absence of robust clinical evidence or well-established operational methodologies.

Because of the associated costs, the inclusion of the number 4 brings attention to this point, however, when attempting to implement this viewpoint on a large scale, it is necessary to take into consideration both healthcare systems and individuals, one of the most important aspects to take into consideration when deciding on a course of therapy is the potential benefits with regard to the expenses of stem cell treatments, efficiency and rationale for application: A mean score of 3.60 on the economics of stem cell therapies (Q6) suggests a favorable view on the cost-effectiveness of these treatments, this score also represents a positive outlook on the efficiency of the treatments.

According to the results of the survey, there is a significant disparity between the level of information that patients possess (Question 7) and the level of regulatory measures that are adequate (Question 8), after receiving a mean score of 3.68 on the knowledge scale, it is evident that patients have a significant amount of information about the several stem cell therapies that are now available, when it comes to the regulatory criteria, however, the average score of 3.52 raises questions about the degree to that the laws as they now stand ensure the safety of patients dealing with treatment-related issues, this brings to light a constant challenge that the sector faces, that is the challenge of striking a balance between being creative and conforming to stringent safety rules.

In response to question 9, the average response (mean: 3.19), it seems that respondents had a cautious but optimistic outlook on the potential for future discoveries in stem cell research, as well as the training requirements in this field, despite the fact that this indicates that there is opportunity for improvement, it also raises issues about the most effective way to incorporate these innovations into orthopaedic care systems, Q10 (averaging 3.45), that underscores the accepted necessity for orthopaedic surgeons to have further training in order to properly carry out stem cell therapies, highlights the fact that training is necessary, better training may make it possible to achieve more effective implementation and outcomes in clinical settings, according to the findings of the study investigation.

In spite of the fact that there is a great deal of enthusiasm about the potential benefits, that include quicker recoveries and improved functional outcomes, there are also a great deal of concerns around safety, regulatory monitoring, and the want for additional training, considering these findings, it is clear that there is a pressing want for continuous education and study into these matters in order to enhance the therapeutic potential of stem cells for orthopedic treatment, future study should be on putting an emphasis on the use of longitudinal data as a means of evaluating the results of patients and gaining a more in-depth comprehension of the ways in that stem cells have the potential to enhance orthopaedic therapy, the purpose of this study is to investigate the perspectives of medical professionals about the use of stem cells in orthopaedics.

References

- Ahmad Z, Wardale J, Brooks R, Henson F, Noorani A, Rushton N. Exploring the application of stem cells in tendon repair and regeneration. Arthroscopy. 2012 Jul;28(7):1018-29.

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

- Akgun I, Unlu MC, Erdal OA, et al, Matrix-induced autologous mesenchymal stem cell implantation versus matrix-induced autologous chondrocyte implantation in the treatment of chondral defects of the knee: a 2-year randomized study. Archives of orthopaedic and trauma surgery. 2015;135(2):251-63. PMID: 25548122
- Akpancar, S., Tatar, O., Turgut, H., Akyildiz, F., & Ekinci, S. (2016). The Current Perspectives of Stem Cell Therapy in Orthopedic Surgery.
- American Academy of Orthopaedic Surgeons. Evidence-based Clinical Practice Guidelines. Management of Osteoarthritis of the Knee (Non Arthroplasty). Published August 2021. Accessed January 25, 2023. Available at URL address: www.aaos.org/oak3cpg
- American Academy of Orthopaedic Surgeons. Evidence-based Clinical Practice Guidelines. Management of Glenohumeral Joint Osteoarthritis. Publsished March 2020. Accessed January 25, 2023. Available at URL address:www.aaos.org/gjocpg
- American Academy of Orthopaedic Surgeons. Evidence-based Clinical Practice Guidelines. Management of Osteoarthritis of the Hip (Non Arthroplasty). Published March 2017, 2021 update pending). Accessed January 25, 2023. Available at URL address: www.aaos.org/
- American Academy of Orthopaedic Surgeons. Management of Glenohumeral Joint Osteoarthritis Evidence-Based Clinical Practice Guideline. [cited 11/10/2023]. 'Available from:' https://www.aaos.org/globalassets/quality-and-practice resources/glenohumeral/gjo-cpg.pdf.
- American Association of Orthopaedic Surgeons. Position Statement. Use of emerging biologic treatments. Position Statement 1187. December 2017 American Academy of orthopaedic Surgeons.
- Anna Clasina van den Boom, N., Winters, M., Jacobs Haisma, H., & Hendrik Moen, M. (2020). Efficacy of Stem Cell Therapy for Tendon Disorders: A Systematic Review.
- Arshi, A., Petrigliano, F. A., Williams, R. J., & Jones, K. J. (2020). Stem cell treatment for knee articular cartilage defects and osteoarthritis. Current reviews in musculoskeletal medicine, 13, 20-27.
- Bastos R, Mathias M, Andrade R, et al, Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2020;28(6):1989-99. PMID: 31587091
- Beom Kim, G. & Shon, O. J. (2020). Current perspectives in stem cell therapies for osteoarthritis of the knee.
- Bistolfi A, Roato I, Fornelli G, Sabatini L, Massè A, Ferracini R. Treatment of knee osteoarthritis by intra-articular injection of concentrated autologous adipose tissue: a twenty four month follow-up study. Int Orthop. 2021 Mar;45(3):627-633.
- Boffa A, Previtali D, Di Laura Frattura G, Vannini F, Candrian C, Filardo G. Evidence on ankle injections for osteochondral lesions and osteoarthritis: a systematic review and meta-analysis. Int Orthop. 2021 Feb;45(2):509-523.
- Borakati A, Mafi R, Mafi P, et al, A Systematic Review And Meta-Analysis of Clinical Trials of Mesenchymal Stem Cell Therapy for Cartilage Repair. Current stem cell research & therapy. 2018;13(3):215-25. PMID: 28914207
- Borakati A, Mafi R, Mafi P, Khan WS. A Systematic Review And Meta-Analysis of Clinical Trials of Mesenchymal Stem Cell Therapy for Cartilage Repair. Curr Stem Cell Res Ther (abstract). 2018 Feb 23;13(3):215-225.
- Burke J, Hunter M, Kolhe R, Isales C, Hamrick M, Fulzele S. Therapeutic potential of mesenchymal stem cell based therapy for osteoarthritis. Clin Transl Med. 2016 Dec;5(1):27.
- Carneiro, D. D. C., Araújo, L. T. D., Santos, G. C., Damasceno, P. K. F., Vieira, J. L., Santos, R. R. D., ... & Soares, M. B. P. (2023). Clinical trials with mesenchymal stem cell therapies for osteoarthritis: challenges in the regeneration of articular cartilage. International Journal of Molecular Sciences, 24(12), 9939.
- Centeno C, Fausel Z, Stemper I, Azuike U, Dodson E. A Randomized Controlled Trial of the Treatment of Rotator Cuff Tears with Bone Marrow Concentrate and Platelet Products

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

Compared to Exercise Therapy: A Midterm Analysis. Stem Cells Int. 2020 Jan 30;2020:5962354.

- Centeno C, Markle J, Dodson E, et al, Symptomatic anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow concentrate and platelet products: a non-controlled registry study. J Transl Med. 2018a Sep 3;16(1):246.
- Centeno C, Schultz JR, Cheever M, et al, A Case Series of Percutaneous Treatment of Non Union Fractures withAutologous, Culture Expanded, Bone Marrow Derived, Mesenchymal Stem Cells and Platelet Lysate. Journal of Bioengineering & Biomedical Science. 2011, S2.
- Centeno C, Sheinkop M, Dodson D, et al, A specific protocol of autologous bone marrow concentrate and platelet products versus exercise therapy for symptomatic knee osteoarthritis: a randomized controlled trial with 2 year follow-up. J Trans Med. 2018b; 16:355.
- Centeno CJ, Al-Sayegh H, Freeman MD, et al, A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop. 2016 Aug;40(8):1755 1765.
- Centeno CJ, Berger DR, Money BT, Dodson E, Urbanek CW, Steinmetz NJ. Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content. Int Orthop. 2022 Oct;46(10):2219-2228.
- Centeno CJ, Pitts J, Al-Sayegh H, Freeman MD. Anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow nucleated cells: a case series. J Pain Res. 2015 Jul 31;8:437-47.
- Centeno CJ, Pitts JA, Al-Sayegh H, Freeman MD. Efficacy and Safety of Bone Marrow Concentrate for Osteoarthritis of the Hip; Treatment Registry Results for 196 Patients. J Stem Cell Res Ther 2014, 4-10.
- Chew E, Prakash R, Khan W. Mesenchymal stem cells in human meniscal regeneration: A systematic review. Ann Med Surg (Lond). 2017 Oct 5;24:3-7.
- Chirba MA, Sweetapple B, Hannon CP, et al, FDA regulation of adult stem cell therapies as used in sports medicine. The journal of knee surgery. 2015;28(1):55-62. PMID: 25603042
- Cook J, Young M. Biologic therapies for tendon and muscle injury. UpToDate®. July 10, 2019, Updated August 2022.
- Cui GH, Wang YY, Li CJ, et al, Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: A meta-analysis. Experimental and therapeutic medicine. 2016;12(5):3390-400. PMID: 27882169
- Cui GH, Wang YY, Li CJ, Shi CH, Wang WS. Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: A meta-analysis. Exp Ther Med. 2016 Nov;12(5):3390-3400.
- De Francesco F, Gravina P, Busato A, Farinelli L, Soranzo C, Vidal L, Zingaretti N, Zavan B, Sbarbati A, Riccio M, Gigante A. Stem Cells in Autologous Microfragmented Adipose Tissue: Current Perspectives in Osteoarthritis Disease. Int J Mol Sci. 2021 Sep 22;22(19):10197.
- Deans TL, Elisseeff JH. Stem cells in musculoskeletal engineered tissue. Curr Opin Biotechnol. 2009;20(5):537-44. PMID: 19879127
- Dec, P., Żyłka, M., Burszewski, P., Modrzejewski, A., & Pawlik, A. (2024). Recent Advances in the Use of Stem Cells in Tissue Engineering and Adjunct Therapies for Tendon Reconstruction and Future Perspectives.
- Delanois RE, Etcheson JI, Sodhi N, Henn RF 3rd, Gwam CU, George NE, Mont MA. Biologic Therapies for the Treatment of Knee Osteoarthritis. J Arthroplasty. 2019 Apr;34(4):801 813.
- DeLong JM, Bradley JP. The current state of stem cell therapies in sports medicine. Oper Tech Orthop 26:124-134. 2016.
- Di Matteo B, El Araby MM, D'Angelo A, et al, Adipose-Derived Stem Cell Treatments and Formulations. Clin Sports Med. 2019 Jan;38(1):61-78.
- Di Matteo B, Vandenbulcke F Vitale ND, et al, Minimally Manipulated Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Systematic Review of Clinical Evidence. Stem Cells Int. 2019 Aug 14;2019:1735242.

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

- Doyle, E. C., Wragg, N. M., & Wilson, S. L. (2020). Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis. Knee Surgery, Sports Traumatology, Arthroscopy, 28, 3827-3842.
- Eastlack RK, Garfin SR, Brown CR, et al, Osteocel Plus cellular allograft in anterior cervical discectomy and fusion: evaluation of clinical and radiographic outcomes from a prospective multicenter study. Spine. 2014;39(22):E1331-7. PMID: 25188591
- Eder, C., Schmidt-Bleek, K., Geissler, S., Andrea Sass, F., Maleitzke, T., Pumberger, M., Perka, C., N. Duda, G., & Winkler, T. (2020). Mesenchymal stromal cell and bone marrow concentrate therapies for musculoskeletal indications: a concise review of current literature.
- Elgaz S, Bonig H, Bader P. Mesenchymal stromal cells for osteonecrosis. J Transl Med. 2020 Oct 20;18(1):399. doi: 10.1186/s12967-020-02565-9.
- Emadedin M, Labibzadeh N, Liastani MG, et al, Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018;20(10):1238-46. PMID: 30318332
- Emadedin M, Labibzadeh N, Liastani MG, et al, Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018 Oct;20(10):1238-1246.
- Evensen, J. H., & Mehta, A. C. (2021). How can orthopedic surgeons support and protect patients as stem cell use evolves? JBJS Open Access. Joshi, A., Kostur, M., & Singhal, N. (2022). Mesenchymal stem cells and considerations using these cells in orthopaedic trauma and critical care.
- Filardo G, Madry H, Jelic M, et al, Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2013;21(8):1717-29. PMID: 23306713
- Filardo G, Madry H, Jelic M, et al, Mesenchymal Stem Cells for the Treatment of Cartilage Lesions: From Preclinical Findings to Clinical Application in Orthopaedics. Knee Surg Sports Traumatol Arthrosc 2013 aug;21(8):1717-29.
- Freitag, J., Chamberlain, M., Wickham, J., Shah, K., Cicuttini, F., Wang, Y., ... & Wickramasinghe, I. (2024). Safety and efficacy of an allogeneic adipose-derived mesenchymal stem cell preparation in the treatment of knee osteoarthritis: A Phase I/IIa randomised controlled trial. Osteoarthritis and Cartilage Open, 6(3), 100500.
- Gangji V, Hauzeur JP. Cellular-based therapy for osteonecrosis. Orthop Clin N Am 40 (2009) 213–221.
- Garza JR, Campbell RE, Tjoumakaris FP, et al, Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. The American journal of sports medicine. 2020;48(3):588-98. PMID: 32109160
- Garza JR, Campbell RE, Tjoumakaris FP, Freedman KB, Miller LS, Santa Maria D, Tucker BS. Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. Am J Sports Med. 2020 Mar;48(3):588-598.
- Gepstein L, Skorecki K. Regenerative Medicine, Cell and Gene Therapies. Goldman-Cecil Medicine 38, 183-195. 26th edition. Copyright 2020 by Elsevier.
- Goldberg A, Mitchell K, Soans J, et al, The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review. J Ortho Surg Res. Mar 09 2017;12(1):39.
- Ha CW, Park YB, Kim SH, Lee HJ. Intra-articular Mesenchymal Stem Cells in Osteoarthritis of the Knee: A Systematic Review of Clinical Outcomes and Evidence of Cartilage Repair. Arthroscopy. 2019 Jan;35(1):277-288.e2.
- Hauzeur JP, De Maertelaer V, Baudoux E, et al, Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

randomized controlled double-blind trial. International orthopaedics. 2017. PMID: 28988340

- Hernigou J, Vertongen P, Rasschaert J, Hernigou P. Role of Scaffolds, Subchondral, Intra Articular Injections of Fresh Autologous Bone Marrow Concentrate Regenerative Cells in Treating Human Knee Cartilage Lesions: Different Approaches and Different Results. Int J Mol Sci. 2021 Apr 8;22(8):3844.
- Hernigou P, Bouthors C, Bastard C, Flouzat Lachaniette CH, Rouard H, Dubory A. Subchondral bone or intra-articular injection of bone marrow concentrate mesenchymal stem cells in bilateral knee osteoarthritis: what better postpone knee arthroplasty at fifteen years? A randomized study. Int Orthop. 2021 Feb;45(2):391-399. doi: 10.1007/s00264 020-04687-7.
- Hogan MV, Walker GN, Cui LR, et al., The role of stem cells and tissue engineering in orthopaedic sports medicine: Current evidence and future directions. Arthroscopy: The Journal of Arthroscopy and Related Surgery. May 2015;31:5:1017-1021.
- Hogan, M. V., Matava, M. J., Sheth, U., Starkey, C., & Brown, R. (2015). Osteoarthritis affects sports medicine.
- Hui, J. H. P., Azura, M., & Lee, E. H. (2009). Review article: stem cell therapy in orthopaedic surgery: current status and ethical considerations.
- Hurley ET, Yasui Y, Gianakos AL, et al, Limited evidence for adipose-derived stem cell therapy on the treatment of osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2018 Nov;26(11):3499-3507.
- Hwan Lee, D., Ae Kim, S., Song, J. S., Ananthram Shetty, A., Kim, B. H., & Jung Kim, S. (2022). Cartilage Regeneration Using Human Umbilical Cord Blood Derived Mesenchymal Stem Cells: A Systematic Review and Meta-Analysis.
- Iijima H, Isho T, Kuroki H, et al, Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: a meta-analysis toward the establishment of effective regenerative rehabilitation. NPJ Regenerative medicine. 2018;3:15. PMID: 30245848
- Injury. Kim, S. J., Ok, J., & Jang, S. J. (2013). Bone Regeneration and Repair. Biomimetics: Advancing Nanobiomaterials and Tissue Engineering.
- International Society for Stem Cell Research. Types of stem cells. 2023 International Society of Stem Cell Research. Accessed Feb 19, 2024. Available at URL address: https://www.closerlookatstemcells.org/learn-about-stem-cells/types-of-stem-cells/
- Jevotovsky DS, Alfonso AR, Einhorn TA, Chiu ES. Osteoarthritis and stem cell therapy in humans: a systematic review. Osteoarthritis Cartilage. 2018 Jun;26(6):711-729.
- Jiang, P., Mao, L., Qiao, L., Lei, X., Zheng, Q., & Li, D. (2021). Efficacy and safety of mesenchymal stem cell injections for patients with osteoarthritis: a meta-analysis and review of RCTs. Archives of orthopaedic and trauma surgery, 141, 1241-1251.
- Jin L, Yang G, Men X, et al, Intra-articular Injection of Mesenchymal Stem Cells After High Tibial Osteotomy: A Systematic Review and Meta-analysis. Orthop J Sports Med. 2022;10(11):23259671221133784. PMID: 36452339
- Kaiser MG, Groff MW, Watters WC, 3rd, et al, Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 16: bone graft extenders and substitutes as an adjunct for lumbar fusion. J Neurosurg Spine. 2014;21(1):106-32. PMID: 24980593.
- Kehoe O, Cartwright A, Askari A, El Haj AJ, Middleton J. Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritis. J Transl Med. 2014 Jun 3;12:157.
- Khan S, Mafi P, Mafi R, Khan W. A Systematic Review of Mesenchymal Stem Cells in Spinal Cord Injury, Intervertebral Disc Repair and Spinal Fusion. Curr Stem Cell Res Ther. 2018;13(4):316-323.
- Kim JH, Kim KI, Yoon WK, Song SJ, Jin W. Intra-articular Injection of Mesenchymal Stem Cells After High Tibial Osteotomy in Osteoarthritic Knee: Two-Year Follow-up of

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

Randomized Control Trial. Stem Cells Transl Med. 2022 Jun 22;11(6):572-585.

- Kim KI, Kim MS, Kim JH. Intra-articular Injection of Autologous Adipose-Derived Stem Cells or Stromal Vascular Fractions: Are They Effective for Patients With Knee Osteoarthritis? A Systematic Review With Meta-analysis of Randomized Controlled Trials. Am J Sports Med. 2022 Jan 12:3635465211053893.
- Kleinschmidt, A. C., Singh, A., Hussain, S., Lovell, G. A., & Shee, A. W. (2022). How effective are non-operative intra-articular treatments for bone marrow lesions in knee osteoarthritis in adults? A systematic review of controlled clinical trials. Pharmaceuticals, 15(12), 1555.
- Koh YG, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, Choi YJ. Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. Arthroscopy. 2013 Apr;29(4):748-55.
- Koh YG, Kwon OR, Kim YS, et al, Adipose-Derived Mesenchymal Stem Cells With Microfracture Versus Microfracture Alone: 2-Year Follow-up of a Prospective Randomized Trial. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2016;32(1):97-109. PMID: 26585585
- Koh YG, Kwon OR, Kim YS, et al, Comparative outcomes of open-wedge high tibial osteotomy with platelet-rich plasma alone or in combination with mesenchymal stem cell treatment: a prospective study. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2014;30(11):1453-60. PMID: 25108907
- Kolasinski SL, Neogi T, Hochberg MC, et al, 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-62. PMID: 31908149
- Kolasinski SL, Neogi T, Hochberg MC, et al, 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). Feb 2020; 72(2): 149-162.
- Kon, E., Boffa, A., Andriolo, L., Di Martino, A., Di Matteo, B., Magarelli, N., ... & Filardo, G. (2023). Combined subchondral and intra-articular injections of bone marrow aspirate concentrate provide stable results up to 24 months. Knee Surgery, Sports Traumatology, Arthroscopy, 31(6), 2511-2517.
- Kphitz, A.-L., & Sucan, M. L. (2020). Stem Cell Application for Orthopedic Regeneration Medicine: Prevention and Management of an Oncoming Journal Level COVID-19 Crisis or A Peripheral Sub-Domain Relevance Reliquary Activities? Open Journal of Regenerative Medicine, 0, 1-5.
- Lamo-Espinosa JM, Prósper F, Blanco JF, Sánchez-Guijo F, Alberca M, García V, González Vallinas M, García-Sancho J. Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis. J Transl Med. 2021 Dec 11;19(1):506.
- Lamo-Espinosa, J. M., Mora, G., Blanco, J. F., Granero-Molto, F., Nunez-Cordoba, J. M., Sanchez-Echenique, C., et al, (2018). Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med, 16, 8.
- Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical Trial. Stem Cells Transl Med. 2019 Jun;8(6):504-511.
- Lee WY, Wang B. Cartilage repair by mesenchymal stem cells: Clinical trial update and perspectives. J Orthop Translat. 2017 Apr 9;9:76-88.
- Li J, Su P, Li J, Chen G, Xiong Y. Efficacy and Safety of Stem Cell Combination Therapy for Osteonecrosis of the Femoral Head: A Systematic Review and Meta-Analysis. J Healthc Eng. 2021 Sep 24;2021:9313201.

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

- Liang, W., Zhou, C., Bai, J., Zhang, H., Jiang, B., Wang, J., Fu, L., Long, H., Huang, X., Zhao, J., & Zhu, H. (2024). Current advancements in therapeutic approaches in orthopedic surgery: a review of recent trends.
- Lim HC, Park YB, Ha CW, et al, Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up. Orthop J Sports Med. 2021;9(1):2325967120973052. PMID: 33490296
- Lin KM, Wang D, Dines JS. Injection therapies for rotator cuff disease. Orthop Clin N Am 49 (2018) 231–239.
- Loukogeorgakis SP, De Coppi P. Stem cells from amniotic fluid--Potential for regenerative medicine. Best Pract Res Clin Obstet Gynaecol. 2016 Feb;31:45-57.
- Ma W, Liu C, Wang S, et al, Efficacy and safety of intra-articular injection of mesenchymal stem cells in the treatment of knee osteoarthritis. A systematic review and meta analysis. Medicine (Baltimore). 2020 Dec 4;99(49):e23343.
- Maheshwer B, Polce EM, Paul K, et al, Regenerative Potential of Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis and Chondral Defects: A Systematic Review and Meta-analysis. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2021;37(1):362-78. PMID: 32497658
- Marks PW, Witten CM, Califf RM. Clarifying Stem-Cell Therapy's Benefits and Risks. N Engl J Med. 2017 Mar 16;376(11):1007-1009.
- Matava, M. J. (2016). Mesenchymal stem cells (MSCs) may regenerate and repair tissue like bone, cartilage, and muscle cells.
- McCulloch, K. L., Luttges, J. W., Montana, D., Collins, C., Ozanich, B. N., & Cameron, H. G. (2021). Recommended 3 basics for musculoskeletal medicine and joint care: 1. Optimal dose regenerative injections, 2. Optimizing non-surgical orthopedic care, 3. Recommendations to establish best practices for a nonoperative musculoskeletal wellness clinic. International Journal of Spine Surgery.
- Mott, A., Mitchell, A., McDaid, C., Harden, M., Grupping, R., Dean, A., Byrne, A., Doherty, L., & Sharma, H. (2020). Systematic review assessing the evidence for the use of stem cells in fracture healing.
- Orth, P., Rey-Rico, A., K Venkatesan, J., Madry, H., & Cucchiarini, M. (2014). Current perspectives in stem cell research for knee cartilage repair.
- Ossendorff, R., Menon, A., A. Schildberg, F., S. Randelli, P., Scheidt, S., Burger, C., C. Wirtz, D., & Cucchi, D. (2023). A Worldwide Analysis of Adipose-Derived Stem Cells and Stromal Vascular Fraction in Orthopedics: Current Evidence and Applications.
- Park YB, Ha CW, Rhim JH, et al, Stem Cell Therapy for Articular Cartilage Repair: Review of the Entity of Cell Populations Used and the Result of the Clinical Application of Each Entity. The American journal of sports medicine. 2018;46(10):2540-52. PMID: 29023156
- Prieto-González, A., VanItallie, T., Rosenbaum, D., & Awan, S. (2021). Injuries cause pain, mobility difficulties, and a long recovery period.
- Rahim, K., Starkey, C., & Brown, R. (2019). Mesenchymal stem cells (MSCs) may promote ligament and tendon regeneration.
- Reicher, M. A. (2018). Bone Marrow Aspirate Performance in Humans. In K. Mithoefer (Ed.), Bone Marrow Aspirate-Concentrate: Basic Science and Clinical Implications (1st ed.). Springer.
- Rinonapoli G, Gregori P, Di Matteo B, et al, Stem cells application in meniscal tears: a systematic review of pre-clinical and clinical evidence. Eur Rev Med Pharmacol Sci. 2021;25(24):7754-64. PMID: 34982437
- Rosenbaum, D., & Awan, S. (2017). Injuries cause pain and impair athlete's performance.
- Ruane, J. J., Ross, A., Zigmont, V., McClure, D., & Gascon, G. (2021). A single-blinded randomized controlled trial of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee with active control. Journal of Stem Cells & Regenerative Medicine, 17(1), 3.

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

- Rush SM, Hamilton GA, Ackerson LM. Mesenchymal stem cell allograft in revision foot and ankle surgery: a clinical and radiographic analysis. The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons. 2009;48(2):163-9. PMID: 19232968
- Samara, O., Jafar, H., Hamdan, M., Al-Ta'mari, A., Rahmeh, R., Hourani, B., ... & Awidi, A. (2022). Ultrasound-guided intra-articular injection of expanded umbilical cord mesenchymal stem cells in knee osteoarthritis: a safety/efficacy study with MRI data. Regenerative Medicine, 17(5), 299-312.
- Saw KY, Anz A, Siew-Yoke Jee C, et al, Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2013;29(4):684-94. PMID: 23380230
- Schmitz, C., Alt, C., A. Pearce, D., P. Furia, J., Maffulli, N., & U. Alt, E. (2022). Methodological Flaws in Meta-Analyses of Clinical Studies on the Management of Knee Osteoarthritis with Stem Cells: A Systematic Review.
- Sen RK, Tripathy SK, Aggarwal S, et al, Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. The Journal of arthroplasty. 2012;27(5):679-86. PMID: 22000577
- Sheth, U. (2020). Osteoarthritis demands novel therapies in sports medicine.
- Starkey, C., & Brown, R. (2015). Mesenchymal stem cells may promote ligament and tendon regeneration in sports injuries.
- Vangsness CT, Jr., Farr J, 2nd, Boyd J, et al, Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. The Journal of bone and joint surgery American volume. 2014;96(2):90-8. PMID: 24430407
- VanItallie T. (2019). Injuries impairing athlete's performance are becoming popular in sports medicine.
- Vega A, Martin-Ferrero MA, Del Canto F, et al, Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. Transplantation. 2015;99(8):1681-90. PMID: 25822648
- Wang, J., Zhou, L., Zhang, Y., Huang, L., & Shi, Q. (2020). Mesenchymal stem cells-a promising strategy for treating knee osteoarthritis: a meta-analysis. Bone & Joint Research, 9(10), 719-728.
- Wiggers TG, Winters M, Van den Boom NA, et al, Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials. Br J Sports Med. 2021;55(20):1161-69. PMID: 34039582
- Wong KL, Lee KB, Tai BC, et al, Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years' follow-up. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2013;29(12):2020-8. PMID: 24286801
- Wyles, C. C., Houdek, M. T., Crespo, A., Slager, S. L., Terzic, A., Behfar, A., et al, (2021). Differential activity of dysregulated mesenchymal stem cells derived from patients with cervical and lumbar intervertebral disc degeneration: Interplay between disc and connective tissue degeneration. Translational Research.
- Xia, D., Wu, J., Zhou, F., Wang, S., Zhang, Z., Zhou, P., & Xu, S. (2022). Mapping Thematic Trends and Analysing Hotspots Concerning the Use of Stem Cells for Cartilage Regeneration: A Bibliometric Analysis From 2010 to 2020.
- Xu S, Liu H, Xie Y, et al, Effect of mesenchymal stromal cells for articular cartilage degeneration treatment: a meta-analysis. Cytotherapy. 2015;17(10):1342-52. PMID: 26122717
- Yi H, Wang Y, Liang Q, et al, Preclinical and Clinical Amelioration of Bone Fractures with Mesenchymal Stromal Cells: a Systematic

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 10, 2024

Review and Meta-Analysis. Cell Transplant. 2022;31:9636897211051743. PMID: 35916286.

- Zaffagnini S, Andriolo L, Boffa A, et al, Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up. The American journal of sports medicine. 2022;50(11):2881-92. PMID: 35984721.
- Zhao D, Cui D, Wang B, et al, Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. 2012;50(1):325-30. PMID: 22094904.